The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs submitting...read more
Seer, which is developing next-generation proteome analysis tests for biomedical research, raised $175 million by offering 9.2 million shares at $19, above the range of $16 to $18. The company offered 0.4 million more shares than anticipated. At pricing, Seer...read more
*Note: The IPO commentary below is normally only available on our premium platform, IPO Pro.* Founded by serial biotech entrepreneur Omid Farokhzad with help from well-known scientist Robert Langer, Seer (SEER) is developing next-generation systems that...read more
Seer, which is developing next-generation proteome analysis tests for biomedical research, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18....read more
US IPO Weekly Recap: The IPO market is taught a thing or two in an 8 IPO week
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs submitting...read more
Seer, a developer of protein analysis tools, prices upsized IPO at $19, above the range
Seer, which is developing next-generation proteome analysis tests for biomedical research, raised $175 million by offering 9.2 million shares at $19, above the range of $16 to $18. The company offered 0.4 million more shares than anticipated. At pricing, Seer...read more
Seer looks to unlock the human proteome
*Note: The IPO commentary below is normally only available on our premium platform, IPO Pro.* Founded by serial biotech entrepreneur Omid Farokhzad with help from well-known scientist Robert Langer, Seer (SEER) is developing next-generation systems that...read more
Unlocking the human proteome: Seer sets terms for $150 million IPO
Seer, which is developing next-generation proteome analysis tests for biomedical research, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18....read more